A RELIABLE RP-UPLC-TUV METHOD FOR SIMULTANEOUS ESTIMATION OF CLARITHROMYCIN, AMOXICILLIN, AND VONOPRAZAN IN CO-PACKED PHARMACEUTICAL DOSAGE FORMS: METHOD DEVELOPMENT AND VALIDATION WITH STABILITY INDICATING PROPERTIES

K. ANUSHA; G. SOWJANYA

doi:10.22159/ijap.2024v16i2.50059

Authors

K. ANUSHA GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh-530045, India
G. SOWJANYA GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh-530045, India

DOI:

https://doi.org/10.22159/ijap.2024v16i2.50059

Keywords:

Clarithromycin, Amoxicillin, and Vonoprazan, RP-UPLC, Hibar C18 column, Specificity, Stability indicating

Abstract

Objective: The study aims to develop a reliable RP-UPLC-TUV method for simultaneous estimation of Clarithromycin, Amoxicillin, and Vonoprazan in bulk and combined dosage.

Methods: A simple, specific, and reliable method for determining Clarithromycin, Amoxicillin, and Vonoprazan has been developed using the RP-UPLC method. In order to successfully separate Clarithromycin, Amoxicillin, and Vonoprazan, 1.0 µl of a 100 % level solution was injected into a Hibar C18 (100 x 2.1 mm and 2 µm) column. The mobile phase consisted of Ammonium Acetate and Acetonitrile in equal volumes, and the flow rate was kept at 0.3 ml/min while the detection wavelength was set to 210 nm. Both the column and the injection port were kept at a temperature of 30 °C at all times.

Results: The retention time (RT) of Clarithromycin, Amoxicillin, and Vonoprazan was observed at 1.24 min, 0.97 min and 1.66 min, correspondingly with accepted system suitability. The linear responses were observed for Clarithromycin, Amoxicillin, and Vonoprazan in the range of 25 to 150 µg/ml, 25 to 150 µg/ml and 1 to 6 µg/ml, respectively. The LOD and LOQ values were calculated to 0.07 µg/ml and 0.22 µg/ml for Clarithromycin, 0.81 µg/ml and 2.45 µg/ml for Amoxicillin and 0.03 µg/ml and 0.09 µg/ml for Vonoprazan. The % RSD values of both precision were assessed in the range of 0.8-1.4. The mean recovery of Clarithromycin, Amoxicillin, and Vonoprazan was in the range of 99.66 %-100.88 %. The statistical analysis of the validation parameters confirmed that the approach was reliable in terms of its accuracy, sensitivity, and precision while also exhibiting a high degree of sensitivity. The study of analytes in a variety of stressful situations guarantees the stability of the substances, ensuring that they represent the method's stability indication.

Conclusion: The newly established technique is quite effective in separating Clarithromycin, Amoxicillin, and Vonoprazan from one another. Also separated with excellent resolution were the degradation products that were formed as a result of the stress conditions. The study concluded that the developed method has considerable adoption in the pharmaceutical sector.

Downloads

Download data is not yet available.

References

Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother. 1992 Sep;26(9):1099-108. doi: 10.1177/106002809202600912, PMID 1421677.

Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992 Feb;11(2):137-52. PMID 1312921.

Peters DH, Clissold SP. Clarithromycin a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Jul;44(1):117-64. doi: 10.2165/00003495-199244010-00009, PMID 1379907.

Todd PA, Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990 Feb;39(2):264-307. doi: 10.2165/00003495-199039020-00008, PMID 2184003.

Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1988 Jan;1(1):109-23. doi: 10.1128/CMR.1.1.109, PMID 3060240.

Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016 Dec 21;81-82:1-7. doi: 10.1016/j.curtheres.2016.12.001, PMID 28119763.

Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol. 2001 Feb;96(2):303-14. doi: 10.1111/j.1572-0241.2001.03511.x, PMID 11232668.

Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020 Jun;101(6):743-51. doi: 10.1159/000502287, PMID 31434101.

Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017 Feb;52(2):238-41. doi: 10.1080/00365521.2016.1250157, PMID 27806639.

Sue S, Maeda S. Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication? Gut Liver. 2021 Nov 15;15(6):799-810. doi: 10.5009/gnl20242, PMID 33850058.

Wynn RL. Amoxicillin update. Gen Dent. 1991 Sep-Oct;39(5):322, 324, 326. PMID 1812049.

Chey WD, Mégraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022 Sep;163(3):608-19. doi: 10.1053/j.gastro.2022.05.055, PMID 35679950.

Pires de Abreu LR, Ortiz RM, de Castro SC, Pedrazzoli J Jr. HPLC determination of amoxicillin comparative bioavailability in healthy volunteers after a single dose administration. J Pharm Pharm Sci. 2003 May-Aug;6(2):223-30. PMID 12935434.

Patyra E, Kwiatek K. In-house validation method for quantification of amoxicillin in medicated feedingstuffs with the use of HPLC-DAD technique. J Vet Res. 2020 Jun 20;64(3):433-8. doi: 10.2478/jvetres-2020-0044, PMID 32984635.

Foroutan SM, Zarghi A, Shafaati A, Madadian B, Abolfathi F. Rapid high performance liquid chromatographic method for determination of clarithromycin in human plasma using amperometric detection: application in pharmacokinetic and bioequivalence studies. Iran J Pharm Res. 2013;12Suppl:65-9. PMID 24250673.

Aktas AH, Saridag AM. Liquid chromatographic-chemometric techniques for the simultaneous HPLC determination of lansoprazole, amoxicillin and clarithromycin in commercial preparation. J Chromatogr Sci. 2017 Sep 1;55(8):798-804. doi: 10.1093/chromsci/bmx039, PMID 28449104.

Ünsal SM, Erkan E. Development and validation of a new RP-HPLC method for organic explosive compounds. Turk J Chem. 2022 Feb 25;46(3):923-8. doi: 10.55730/1300-0527.3380, PMID 37720613.

Dobrova AO, Golovchenko OS, Bezruk IV, Ivanauskas L, Georgiyants V. Simultaneous determination of amoxicillin and potassium clavulanate in combined medicinal forms: procedure transfer from HPLC to UPLC. Ceska Slov Farm. 2020 Fall;69(4):186-93. PMID 33291935.

Hassib ST, Taha EA, Sharf MG, Mostafa EA. RP-HPLC-DAD method development and validation for simultaneous determination of lansoprazole, tinidazole, amoxicillin, and naproxen in their raw materials and combined dosage form: DOE approach for optimization of the proposed method. J AOAC Int. 2022 Apr 27;105(3):675-87. doi: 10.1093/jaoacint/qsab159, PMID 34918094.

VanDuyse SA, Fulford MJ, Bartlett MG. ICH Q10 pharmaceutical quality system guidance: understanding its impact on pharmaceutical quality. AAPS J. 2021 Nov 12;23(6):117. doi: 10.1208/s12248-021-00657-y, PMID 34773177.

Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-a review. J Pharm Anal. 2014 Jun;4(3):159-65. doi: 10.1016/j.jpha.2013.09.003, PMID 29403878.

Godela R, Gummadi S. A simple stability indicating RP-HPLC-DAD method for concurrent analysis of tenofovir disoproxil fumarate, Doravirine and lamivudine in pure blend and their combined film-coated tablets. Ann Pharm Fr. 2021 Nov;79(6):640-51. doi: 10.1016/j.pharma.2021.04.006, PMID 34019910.

Ahmad S, Khabiya P, Au T, Raheman Bakhshi A. Quality by design approach to develop stability indicating reversed-phase high-performance liquid chromatography method development for ambroxol. Asian J Pharm Clin Res. 2021 Dec;14(12):44-9. doi: 10.22159/ajpcr.2021.v14i12.42939.

Jaiswal R, Wadetwar R. Development and validation of the Rp-HPLC method for estimation of cilnidipine in rat plasma. Int J Pharm Pharm Sci. 2022 Oct;14(10):32-7. doi: 10.22159/ijpps.2022v14i10.45940.

Aswathy SR, Muthas C, Anjali Sruthy S, Devi Swapna PV, Gopinath U. Validation and application of Rp-HPLC method for quantification of enrofloxacin in pure and veterinary dosage forms. Int J Pharm Pharm Sci. 2022 Feb;14(2):42-7.

Mahajan N, Deshmukh S, Farooqui M. Analytical method development and validation for known and unknown impurities profiling for carvedilol pharmaceutical dosage form (tablets). Int J Curr Pharm Sci. 2021 Nov;13(6):71-80. doi: 10.22159/ijcpr.2021v13i6.1922.

Andhale SM, Nikalje AP. Simultaneous estimation of azilsartan and cilnidipine in bulk by Rp-HPLC and assessment of its applicability in marketed tablet dosage form. Int J App Pharm. 2022 Jan;14(1):116-23. doi: 10.22159/ijap.2022v14i1.42208.

ICH harmonized tripartite guideline. In: Stability testing: photostability testing of new drug substances and products. Vol. Q1B. Geneva, Switzerland: International Council on Harmonization. International Federation of Pharmaceutical Manufacturers Associations; 1996.

ICH harmonized tripartite guideline. Stability testing of new drug substances and new drug products Q1A. Vol. R2. Geneva, Switzerland: International Council on Harmonization. International Federation of Pharmaceutical Manufacturers Associations; 2003.

ICH harmonized tripartite guideline. Validation of analytical procedures: text and methodology, Q2. In: International council on harmonization. Vol. R1. Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations; 2005.